Ellis PM - Search Results

1

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.

Melosky BL, Leighl NB, Dawe D, Blais N, Wheatley-Price PF, Chu QS, Juergens RA, Ellis PM, Sun A, Schellenberg D, Ionescu DN, Cheema PK. Melosky BL, et al. Among authors: ellis pm. Curr Oncol. 2023 Jun 30;30(7):6289-6315. doi: 10.3390/curroncol30070465. Curr Oncol. 2023. PMID: 37504325 Free PMC article. Review.

2

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M. Butts C, et al. J Clin Oncol. 2005 Sep 20;23(27):6674-81. doi: 10.1200/JCO.2005.13.011. J Clin Oncol. 2005. PMID: 16170175 Clinical Trial.

3

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Noble J, et al. Among authors: ellis pm. J Thorac Oncol. 2006 Nov;1(9):1042-58. J Thorac Oncol. 2006. PMID: 17409993 Free article. Review.

4

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA. Butts CA, et al. Among authors: ellis pm. J Clin Oncol. 2007 Dec 20;25(36):5777-84. doi: 10.1200/JCO.2007.13.0856. J Clin Oncol. 2007. PMID: 18089875 Clinical Trial.

5

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA. Crabb SJ, et al. Among authors: ellis pm. J Clin Oncol. 2009 Jan 20;27(3):404-10. doi: 10.1200/JCO.2008.16.2545. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047292

6

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.

Ellis PM, Morzycki W, Melosky B, Butts C, Hirsh V, Krasnoshtein F, Murray N, Shepherd FA, Soulieres D, Tsao MS, Goss G. Ellis PM, et al. Curr Oncol. 2009 Jan;16(1):27-48. doi: 10.3747/co.v16i1.393. Curr Oncol. 2009. PMID: 19229369 Free PMC article.

7

A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.

Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, Pond GR, Dick C, Yen Y, Zwiebel JA, Moore MJ. Leighl NB, et al. J Thorac Oncol. 2009 Sep;4(9):1163-9. doi: 10.1097/JTO.0b013e3181a949b2. J Thorac Oncol. 2009. PMID: 19704337 Free PMC article. Clinical Trial.

8

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Goss GD, et al. Among authors: ellis pm. J Clin Oncol. 2010 Jan 1;28(1):49-55. doi: 10.1200/JCO.2009.22.9427. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917841 Clinical Trial.

9

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.

Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Goffin J, et al. Among authors: ellis pm. J Thorac Oncol. 2010 Feb;5(2):260-74. doi: 10.1097/JTO.0b013e3181c6f035. J Thorac Oncol. 2010. PMID: 20101151 Free article. Review.

10

A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.

Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D. Butts C, et al. Among authors: ellis pm. Clin Lung Cancer. 2010 Nov 1;11(6):391-5. doi: 10.3816/CLC.2010.n.101. Clin Lung Cancer. 2010. PMID: 21071331 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

218 results

Search Page